The last few months have been challenging for the Autoimmunity 2020 congress.

Due to the latest developments regarding the COVID-19 virus we have decided to postpone the Autoimmunity 2020 Congress to May 2021.

The new dates are 29 May - 1 June 2021.

Venue: Athens, Greece

We have already received almost 1000 registrations and the same number of abstracts to the upcoming congress. Our intention is to keep the state-of-the-art program as is and we hope that you will remain part of our faculty at this excellent Congress.

The abstract submission is still open, and you are welcome to submit additional abstracts. 

Please see the revised program on the congress website: https://autoimmunity.kenes.com/scientific-program/  

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation